Clinical Trials

Ovarian Neoplasms

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

BreastGastrointestinalGenitourinaryGynecologic

298 enrolled 18 charts

Ovarian

NCT05320757 2025-06-11

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Phase EARLY_PHASE1 Completed

20 enrolled

Endometrial Neoplasms

NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

189 enrolled

Triple Negative Metastatic Breast Cancer

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

123 enrolled 14 charts

Ovarian Neoplasms

NCT03745950 2024-12-04

UTOLA

147 enrolled

Endometrial Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

40 enrolled 16 charts

Phase EARLY_PHASE1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03378297 2024-10-30

IMPACT

26 enrolled

Ovarian Neoplasms

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

70 enrolled 13 charts

Breast Neoplasms, Ovarian Neoplasms

NCT05700669 2024-09-19

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Phase 1/2 Completed

3 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Ovarian Neoplasms

NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Classical hematologyGynecologic

98 enrolled

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03117933 2024-01-23

OCTOVA

139 enrolled

Ovarian Neoplasms

NCT04152941 2023-09-06

RETROLA

Completed

130 enrolled

Relapsed Ovarian Cancers Patients

NCT04669002 2023-08-02

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

34 enrolled

Ovarian Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

99 enrolled 17 charts

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04417192 2023-07-06

OLAPem

30 enrolled

Ovarian Neoplasms

NCT03470805 2022-09-23

Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

9 enrolled

Ovarian Neoplasms

NCT02476968 2022-09-10

ORZORA

Phase 4 Completed

181 enrolled 24 charts

BRCA or HRR+ Mutated Ovarian Cancer Patients

NCT02477644 2022-08-02

PAOLA-1

Phase 3 Completed

806 enrolled

Ovarian Neoplasms

NCT02282020 2022-07-26

SOLO3

Phase 3 Completed

266 enrolled 31 charts

Ovarian Neoplasms

NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Phase NA Completed

34 enrolled

Ovarian Neoplasms

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

62 enrolled 15 charts

Phase EARLY_PHASE1 Completed

Ovarian Neoplasms

NCT02855697 2022-02-22

MOLTO

28 enrolled

Ovarian Neoplasms

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

BreastGastrointestinalGenitourinaryGynecologicLymphoid

49 enrolled

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

118 enrolled

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT02506816 2020-11-30

Polen

Completed

36 enrolled 10 charts

Endometrial Neoplasms

NCT02121990 2020-08-21

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

17 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01237067 2019-12-17

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

77 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

Classical hematologyGynecologic

97 enrolled 22 charts

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02418624 2019-01-16

REVIVAL